Ropivacaine hydrochloride

Research use only, not for human use.

Ropivacaine is a local anaesthetic drug belonging to the amino amide group.

Ropivacaine is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. (In Vivo):Epidural administration of Ropivacaine hydrochloride effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.Ropivacaine hydrochloride inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).Ropivacaine hydrochloride prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.Ropivacaine hydrochloride inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.

——

Epidural administration of Ropivacaine hydrochloride effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.Ropivacaine hydrochloride inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).Ropivacaine hydrochloride prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.Ropivacaine hydrochloride inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Animal Model:Adult Sprague-Dawley rats (300–400g)Dosage:1 μM Administration:Infusion (added to the perfusate reservoir) Result:Attenuated pressure-dependent increases in filtration coefficient (Kf).

——

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

——

——

98717-15-8

310.86

C17H26N2O·HCl

>98% (HPLC)

DMSO: 10 mM

CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C.Cl

——

(-20℃)

With Ice Pack

≥ 2 years